The Globe and Mail reports in its Thursday, Dec. 4, edition that Hims & Hers Health, one of the largest U.S. telehealth providers, is entering the Canadian market with the acquisition of Montreal-based Livewell on Thursday and expects to benefit from the rising demand for the generic weight-loss drug semaglutide when it becomes available. The Globe's Chris Hannay writes that Semaglutide is currently made by Novo Nordisk and sold under the brand names Ozempic (prescribed primarily for diabetes) and Wegovy (for obesity). Ozempic is Canada's best-selling drug, earning $2.2-billion in the first nine months of 2025, while Wegovy also ranks in the top 10 with $441-million. Hims & Hers says it is most focused on obesity care in its Canadian services, which begin Thursday. A patient can use the virtual platform to speak with a physician or nurse practitioner about their treatment and, if appropriate, get a prescription and order medication that can be delivered to their door. Hims & Hers chief Andrew Dudum highlighted Canada as a key opportunity for expansion due to its high obesity rate -- two-thirds of Canadians are overweight -- and because it is the first major market where semaglutide loses legal protections.